Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial outer membrane lipopolysaccharide (LPS) and phospholipids are fundamental structural components that define the surface of Gram-negative bacteria. LPS, often referred to as endotoxin, is a complex glycolipid composed of three regions: the hydrophobic Lipid A, a core oligosaccharide, and a distal O-antigen (Raetz & Whitfield, 2002, Annu Rev Biochem). These molecules are essential for maintaining the integrity of the outer membrane, acting as a selective permeability barrier that protects the bacterium from toxic substances, including detergents and many antibiotics (Nikaido, 2003, Microbiol Mol Biol Rev). In clinical settings, LPS is a major driver of the pathophysiology of sepsis; its recognition by the host's Toll-like receptor 4 (TLR4) triggers a massive release of pro-inflammatory cytokines (Park & Lee, 2013, Exp Mol Med). Drugs such as polymyxins (Polymyxin B and Colistin) specifically target this site by binding to the negatively charged phosphate groups of LPS and phospholipids. This binding displaces stabilizing divalent cations (Mg2+ and Ca2+), leading to membrane destabilization, increased permeability, and eventual cell lysis (Velkov et al., 2013, J Med Chem). Despite their efficacy against multi-drug resistant pathogens, targeting these lipids presents challenges, including significant nephrotoxicity and the risk of inducing a systemic inflammatory response due to rapid endotoxin release (Falagas & Kasiakou, 2006, Nephrol Dial Transplant). Understanding the interaction between these lipids and therapeutic agents is crucial for the development of next-generation antibiotics targeting the Gram-negative cell envelope.
Disruption of the outer membrane through displacement of divalent cations (Mg2+ and Ca2+), binding to Lipid A to neutralize endotoxin activity, and inhibition of LPS transport proteins (e.g., LptD)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial outer membrane lipopolysaccharide and phospholipid (LPS).